4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout
Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions. Find out which one has held its streak for 64 straight years and whether the 6% yielder is…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Big Pharma has always sold two things to income investors: a fat check and the anxiety that a single patent expiration could shrink the cash flow behind it. The four names below face genuine loss-of-exclusivity risk this decade, yet all four are defending their payouts with diversified launches, deep pipelines, and cash generation that dwarfs the dividend. One standout is Johnson & Johnson which just marked its 64th consecutive year of dividend increases, and it is the anchor for a group that has kept paying through every previous patent cliff that has been thrown at it.
Johnson & Johnson
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) raised its quarterly payout in April to $1.34 per share, a 3.1% increase that marked the 64th consecutive annual raise and reaffirmed its Dividend King status. The annualized forward dividend sits at $5.36 per share against a current share price of $268.95.
Dividend safety here is about as fortified as it gets in large-cap pharma. Management reiterated on the Q2 call that it is on track for full-year 2026 free cash flow approaching $21 billion, with $8.7 billion generated year-to-date and roughly $21 billion in cash and marketable securities on the balance sheet. The payout is covered many times over by cash flow, and the FY2026 adjusted EPS guide of $11.50 to $11.65 leaves ample room over the annualized dividend rate.
The bull case is diversification at scale. J&J now has 28 products and platforms each generating more than $1 billion in annual revenue, and Q2 sales grew 5.6% operationally to $25.3 billion despite an approximate 460 basis point headwind from Stelara. Oncology is the engine, with Darzalex above $4 billion in the quarter and Tremfya delivering 71% growth to $2 billion.
The risk: STELARA biosimilar erosion is real and ongoing, with Stelara sales down 55.7% in Q2. If Tremfya and Icotide fail to backfill the immunology franchise as quickly as management expects, growth flattens even with the rest of the portfolio humming.
Pfizer
Pfizer (NYSE:PFE) carries the highest yield in the group. At $27.95 per share, the trailing dividend yield is 6.14%, which puts it firmly in ultra-high-yield territory. The quarterly payout of $0.43 per share has held since the 2025-01-24 ex-dividend date, with an annualized forward dividend of $1.72.
Pfizer generated $3.45 billion of operating cash flow in Q2 and returned $4.9 billion to shareholders via the dividend in the first half of 2026. Leverage sits at 2.7 times, elevated but manageable, and the company has explicitly ruled out buybacks for 2026 to protect the payout. CEO Albert Bourla was blunt on the call: “We feel extremely confident that we will, even the most stretched scenarios that we are running, we will be able to maintain our dividend.” He added that “the dividend will be maintained and eventually after the LOE period will start again growing it.”
The bull case runs through the launched-and-acquired portfolio, which generated $3.2 billion in Q2 revenue and grew 18% operationally, with PADCEV up over 20%. Management raised full-year revenue guidance to $60.5 billion to $62.5 billion and expects a return to growth from 2029 onward.
The risk: the Eliquis, Vyndaqel, and Ibrance loss-of-exclusivity wave is the largest in the group, and COVID revenue continues to shrink, with full-year COVID guidance revised down to approximately $4 billion from $5 billion. A 6%+ yield is the market’s way of pricing that transition.
Merck
Merck (NYSE:MRK) pays a quarterly dividend of $0.85 per share, with an annualized forward rate of $3.40. Against a share price of $151.04, that is a mid-single-digit yield backed by the strongest oncology franchise in the sector. The dividend was raised from $0.81 to $0.85 with the 2025-12-15 ex-dividend date, continuing a steady annual step-up pattern.
Safety looks solid despite optics: FY2025 non-GAAP EPS came in at $8.98, which comfortably covers the annualized payout. FY2026 EPS guidance of $2.66 to $2.76 is depressed by a $2.31 per share upfront charge tied to the Terns acquisition, so the underlying earnings power remains intact. Management stated plainly: “We remain committed to the dividend with the goal of increasing it over time,” alongside plans for roughly $3 billion in share repurchases in 2026.
The bull case is Keytruda-plus-what-comes-after. The franchise delivered $8.4 billion in Q2 sales, up 4%, and Merck is stacking new growth engines: WINREVAIR sales of $588 million, up 75%, plus more than 20 new products representing over $70 billion of commercial opportunity. CEO Rob Davis called the Keytruda transition “more of a hill than a cliff.”
The risk: KEYTRUDA still represents roughly half of pharma revenues, and the 2028 loss of exclusivity is the single biggest revenue-concentration event any of these four faces. Any slippage in the replacement portfolio would be felt immediately.
Bristol Myers Squibb
Bristol Myers Squibb (NYSE:BMY) trades at $62.50 per share with a quarterly dividend of $0.63 and an annualized forward rate of $2.52. The dividend history is the deepest in the group: 94 consecutive years of dividend payments and 17 consecutive annual increases, both verified against the payment record.
FY2026 non-GAAP EPS is guided to $6.05 to $6.35, easily covering the annualized payout. Q2 operating cash flow was approximately $3.4 billion, and the company paid down another $1.2 billion of debt during the quarter, ending with roughly $11.5 billion in cash and marketable securities. Net debt of around $33.6 billion is the highest constraint here, but it is falling.
The bull case is a growth portfolio finally big enough to matter. Growth-portfolio sales rose 14% in Q2 and now represent nearly 60% of total revenue, led by Eliquis at approximately $4.5 billion, up 21%, plus double-digit gains across Camzyos, Breyanzi, Reblozyl, and Cobenfy. Management expects more than 10 new medicines by the end of the decade, with the Milvexian atrial-fibrillation readout timed to bridge the April 2028 Eliquis U.S. LOE.
The risk: Revlimid and Pomalyst erosion is happening now. Revlimid fell 63% and Pomalyst 22% in Q1 2026 following generic pomalidomide entry in March and unlimited generic lenalidomide from January 31, 2026. The legacy portfolio is expected to decline 12% to 16% in 2026, and the growth portfolio has to keep outrunning that headwind.
Takeaway
These four names give income investors different flavors of the same durability trade. JNJ offers the deepest streak and the widest moat, Merck brings the strongest single franchise plus a pipeline priced for skepticism, Bristol Myers trades on the widest legacy-versus-growth gap, and Pfizer pays the biggest yield in exchange for the largest LOE wave to clear. Payout coverage looks defensible across the group, and every management team went out of its way to reaffirm the dividend in its most recent call.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
